Gender influence on weight‐loss pattern and survival of nonsmall cell lung carcinoma patients

Gender has recently emerged as a discriminating factor in nonsmall lung carcinoma (NSCLC) patient outcome. Since the potential for interaction among established prognostic factors and gender in this common disease has not been explored, the authors evaluated the role of gender and weight‐loss pattern in predicting clinical outcome in a balanced population of men and women presenting with NSCLC.

[1]  Mangalam Sridhar.  Why do patients with emphysema lose weight? , 1995, The Lancet.

[2]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Walsh,et al.  The symptoms of advanced cancer. , 1995, Seminars in oncology.

[4]  A. Bowman,et al.  Serum androgens and gonadotrophins in bronchial carcinoma. , 1993, Respiratory medicine.

[5]  Brown Jk.  Gender, age, usual weight, and tobacco use as predictors of weight loss in patients with lung cancer. , 1993 .

[6]  B. Cheson,et al.  Male-female differences in the impact of cancer therapy. , 1993, Oncology.

[7]  H. Perry,et al.  Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study , 1993, Journal of the American Geriatrics Society.

[8]  D. Ihde,et al.  Chemotherapy of Lung Cancer , 1992 .

[9]  S. Bhasin.  Clinical review 34: Androgen treatment of hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.

[10]  R. Bremnes,et al.  Gonadal endocrine dysfunction in patients with lung cancer: Relation to responsiveness to chemotherapy, respiratory function and performance status , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  M. Fukuoka,et al.  A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma , 1991, Cancer.

[12]  M. Fukuoka,et al.  A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Rowland,et al.  Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. , 1991, International journal of radiation oncology, biology, physics.

[14]  H. Golomb,et al.  Sex-associated differences in presentation and survival in patients with lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Chlebowski,et al.  Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration , 1989, Cancer.

[16]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Groshen,et al.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Nieschlag,et al.  TRANSDERMAL TESTOSTERONE SUBSTITUTION THERAPY FOR MALE HYPOGONADISM , 1986, The Lancet.

[19]  R. Chlebowski,et al.  Influence of nandrolone decanoate on weight loss in advanced non‐small cell lung cancer , 1986, Cancer.

[20]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[21]  G. Secreto,et al.  Abnormal Serum Hormone Levels in Lung Cancer , 1983, Tumori.

[22]  R. Chlebowski,et al.  Hypogonadism in male patients with metastatic cancer prior to chemotherapy. , 1982, Cancer research.

[23]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[26]  J. Osterman.  Androgen replacement therapy. , 1994, Current therapy in endocrinology and metabolism.

[27]  D. Ettinger,et al.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.